Lumega-Z® Demonstrates Superiority in a Head-to-Head Study Showing Better Bioavailability of Carotenoids and Restoring Macular Pigment Density
May 12, 2020 07:05 ET
|
Guardion Health Sciences, Inc.
-- First study to provide a head-to-head comparison of two commercially available supplements with regard to the changes in serum levels of carotenoids, visual function and macular pigment optical...
Guardion Health Sciences Receives $3.5 Million from Exercise of Warrants
March 06, 2020 08:05 ET
|
Guardion Health Sciences, Inc.
San Diego, California, March 06, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), an ocular health sciences company that develops, formulates,...
Guardion® Announces Development of Unique Immuno-Supportive Complex Targeting Upper Respiratory Tract Infections
February 06, 2020 07:00 ET
|
Guardion Health Sciences, Inc.
Formulation will be First Nutraceutical Compound to be Introduced Under Guardion’s Recently Acquired NutriGuard Business Line San Diego, California, Feb. 06, 2020 (GLOBE NEWSWIRE) --...
Guardion® Announces Statistically Significant Blood Assay Study Results
October 10, 2019 10:30 ET
|
Guardion Health Sciences, Inc.
Study Results Show 40 Times Higher Blood Concentration Levels of Mesozeaxanthin From Lumega-Z, Guardion’s Flagship Medical Food, as compared to Standard AREDS2 Over-The-Counter Gel Caps San Diego,...
Guardion Health Sciences Announces Pricing of $5.2 Million Underwritten Public Offering
August 13, 2019 09:00 ET
|
Guardion Health Sciences, Inc.
San Diego, CA, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), announced the pricing of an underwritten public offering of 13,000,000...
Guardion Health Sciences Reports June 30, 2019 Interim Results of Operations
August 12, 2019 08:40 ET
|
Guardion Health Sciences, Inc.
Highlights Include: 18.2% Revenue Growth for the Three Months Ended June 30, 2019 and 21.7% Revenue Growth for the Six Months Ended June 30, 2019 San Diego, CA , Aug. 12, 2019 (GLOBE...
Foundation Fighting Blindness selects Guardion’s VectorVision CSV-1000 Diagnostic Instrument for Use in Large-Scale Multi-Center Clinical Trial
August 06, 2019 07:00 ET
|
Guardion Health Sciences, Inc.
The CSV-1000 Diagnostic Instrument is Considered the Standard of Care for the Measurement of Contrast Sensitivity San Diego, CA, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc....
Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the Hong Kong Patents Registry
July 17, 2019 07:00 ET
|
Guardion Health Sciences, Inc.
San Diego, CA, July 17, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), announced that it has received a patent from the Patents Registry in...
Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the European Union
June 20, 2019 07:00 ET
|
Guardion Health Sciences, Inc.
San Diego, CA, June 20, 2019 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), an ocular health sciences and technologies company that develops,...
Guardion Launches Second Ocular Health Formula ‘GlaucoCetin’
June 04, 2019 07:00 ET
|
Guardion Health Sciences, Inc.
In an IRB-approved trial conducted at the New York Eye and Ear Infirmary, the parent compound of GlaucoCetin, GlaucoHealth, designed by Robert Ritch, MD, successfully reversed mitochondrial...